179 related articles for article (PubMed ID: 36543879)
21. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.
Olcaydu D; Rumi E; Harutyunyan A; Passamonti F; Pietra D; Pascutto C; Berg T; Jäger R; Hammond E; Cazzola M; Kralovics R
Haematologica; 2011 Mar; 96(3):367-74. PubMed ID: 21173100
[TBL] [Abstract][Full Text] [Related]
22. Genomic and Clinicopathologic Characterization of
Kaur H; Salles DC; Murali S; Hicks JL; Nguyen M; Pritchard CC; De Marzo AM; Lanchbury JS; Trock BJ; Isaacs WB; Timms KM; Antonarakis ES; Lotan TL
Clin Cancer Res; 2020 Sep; 26(18):4869-4881. PubMed ID: 32694154
[TBL] [Abstract][Full Text] [Related]
23. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
24. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
Kilpivaara O; Mukherjee S; Schram AM; Wadleigh M; Mullally A; Ebert BL; Bass A; Marubayashi S; Heguy A; Garcia-Manero G; Kantarjian H; Offit K; Stone RM; Gilliland DG; Klein RJ; Levine RL
Nat Genet; 2009 Apr; 41(4):455-9. PubMed ID: 19287384
[TBL] [Abstract][Full Text] [Related]
25. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.
Karlsson Q; Brook MN; Dadaev T; Wakerell S; Saunders EJ; Muir K; Neal DE; Giles GG; MacInnis RJ; Thibodeau SN; McDonnell SK; Cannon-Albright L; Teixeira MR; Paulo P; Cardoso M; Huff C; Li D; Yao Y; Scheet P; Permuth JB; Stanford JL; Dai JY; Ostrander EA; Cussenot O; Cancel-Tassin G; Hoegel J; Herkommer K; Schleutker J; Tammela TLJ; Rathinakannan V; Sipeky C; Wiklund F; Grönberg H; Aly M; Isaacs WB; Dickinson JL; FitzGerald LM; Chua MLK; Nguyen-Dumont T; ; Schaid DJ; Southey MC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2021 Aug; 4(4):570-579. PubMed ID: 33436325
[TBL] [Abstract][Full Text] [Related]
26. Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene.
Tavera-Tapia A; Pérez-Cabornero L; Macías JA; Ceballos MI; Roncador G; de la Hoya M; Barroso A; Felipe-Ponce V; Serrano-Blanch R; Hinojo C; Miramar-Gallart MD; Urioste M; Caldés T; Santillan-Garzón S; Benitez J; Osorio A
Breast Cancer Res Treat; 2017 Feb; 161(3):597-604. PubMed ID: 27913932
[TBL] [Abstract][Full Text] [Related]
27. CHST15 gene germline mutation is associated with the development of familial myeloproliferative neoplasms and higher transformation risk.
Chen Y; Zhang Y; Wang Z; Wang Y; Luo Y; Sun N; Zheng S; Yan W; Xiao X; Liu S; Li J; Peng H; Xu Y; Hu G; Cheng Z; Zhang G
Cell Death Dis; 2022 Jul; 13(7):586. PubMed ID: 35798703
[TBL] [Abstract][Full Text] [Related]
28. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene.
Hsu FC; Roberts NJ; Childs E; Porter N; Rabe KG; Borgida A; Ukaegbu C; Goggins MG; Hruban RH; Zogopoulos G; Syngal S; Gallinger S; Petersen GM; Klein AP
JAMA Oncol; 2021 Nov; 7(11):1664-1668. PubMed ID: 34529012
[TBL] [Abstract][Full Text] [Related]
29. ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations.
McDuff SGR; Bellon JR; Shannon KM; Gadd MA; Dunn S; Rosenstein BS; Ho AY
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1373-1382. PubMed ID: 33545302
[TBL] [Abstract][Full Text] [Related]
30. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
31. The Genetic Makeup of Myeloproliferative Neoplasms: Role of Germline Variants in Defining Disease Risk, Phenotypic Diversity and Outcome.
Masselli E; Pozzi G; Carubbi C; Vitale M
Cells; 2021 Sep; 10(10):. PubMed ID: 34685575
[TBL] [Abstract][Full Text] [Related]
32. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
33. Germline
Braunstein EM; Chen H; Juarez F; Yang F; Tao L; Makhlin I; Williams DM; Chaturvedi S; Pallavajjala A; Karantanos T; Martin R; Wohler E; Sobreira N; Gocke CD; Moliterno AR
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209587
[TBL] [Abstract][Full Text] [Related]
34. Diversity of ATM gene variants: a population-based genome data analysis for precision medicine.
Fukunaga H; Taki Y; Prise KM
Hum Genomics; 2019 Aug; 13(1):38. PubMed ID: 31443742
[TBL] [Abstract][Full Text] [Related]
35. Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
Petrackova A; Savara J; Turcsanyi P; Gajdos P; Papajik T; Kriegova E
Br J Haematol; 2022 Nov; 199(3):371-381. PubMed ID: 36029002
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer.
Pylkäs K; Tommiska J; Syrjäkoski K; Kere J; Gatei M; Waddell N; Allinen M; Karppinen SM; Rapakko K; Kääriäinen H; Aittomäki K; Blomqvist C; Mustonen A; Holli K; Khanna KK; Kallioniemi OP; Nevanlinna H; Winqvist R
Carcinogenesis; 2007 May; 28(5):1040-5. PubMed ID: 17166884
[TBL] [Abstract][Full Text] [Related]
37. Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma.
Wójcicka A; Czetwertyńska M; Świerniak M; Długosińska J; Maciąg M; Czajka A; Dymecka K; Kubiak A; Kot A; Płoski R; de la Chapelle A; Jażdżewski K
Genes Chromosomes Cancer; 2014 Jun; 53(6):516-23. PubMed ID: 24599715
[TBL] [Abstract][Full Text] [Related]
38. The roles of sex and genetics in the MPN.
Moliterno AR; Braunstein EM
Int Rev Cell Mol Biol; 2022; 366():1-24. PubMed ID: 35153002
[TBL] [Abstract][Full Text] [Related]
39. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
[TBL] [Abstract][Full Text] [Related]
40. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
